News Sentiment
-40.0
Negative
DATA LIVE
Loading ...
Asset-specific news intelligence
Ionis Pharmaceuticals, Inc. Common Stock
Aggregated sentiment, estimated market impact and analysis confidence from recent articles linked to this asset. This feature is independent of the overall stock score.
All recent articles have completed sentiment assessments.
As of
Aug 21, 2026, 12:52 AM
News Sentiment
-40.0
Negative
Estimated Impact
75.0
Weighted estimate of how strongly the analyzed news may affect the asset.
Analysis Confidence
85.0
Confidence in the asset-specific article assessments, not historical model reliability.
Processing state of all articles inside the selected window.
Articles
1
Available
1
Pending
0
Failed
0
Unassessed
0
Latest analyzed article
Aug 15, 2026, 4:38 AM
Counts include only articles with an available assessment.
Positive
0
Neutral
0
Negative
1
High impact
1
Latest article
Aug 14, 2026, 10:15 AM
Showing 1–1 of 1 articles
Ionis Pharmaceuticals stock has fallen 30% year-to-date following the failure of its heart drug Eplontersen in clinical trials. However, the company showed mixed results: Q2 revenue declined 41% year-over-year (excluding a one-time payment), but adjusted revenue grew 56%. The company received FDA approval for Tryngolza for severe hypertriglyceridemia and saw strong growth in Dawnzera sales. Despite the setback, Wall Street maintains a strong buy rating with a $115 price target, though investors remain concerned about Tryngolza's commercial traction and competition from Arrowhead Pharmaceuticals.
Analysis summary
The article reports a significant 30% year-to-date decline in Ionis Pharmaceuticals' stock price due to the failure of its heart drug Eplontersen in clinical trials, which is a major negative event for the asset. However, the company also received FDA approval for Tryngolza and reported strong growth in Dawnzera sales, along with adjusted revenue growth of 56%, indicating some positive operational